CRP and metastatic prostate carcinoma: In addition, CRP also predicted a poor survival in metastatic prostate cancer no matter treated with chemotherapy15, 19 (OS: fixed-effect model; [HR] = 2.18, 95% CI = 1.55–3.07; p < 0.01) (Supplementary Figure S1C online)or endocrine therapy14, 16 (CSS: fixed-effect model; [HR] = 1.92, 95% CI = 1.22–3.03; p < 0.01) (Supplementary Figure S1D online).